YB-1 activating cascades as potential targets in KRAS-mutated tumors
AbstractY ‑box binding protein‑1 (YB-1) is a multifunctional protein that is highly expressed in human solid tumors of various entities. Several cellular processes,e.g. cell cycle progression, cancer stemness and DNA damage signaling that are involved in the response to chemoradiotherapy (CRT) are tightly governed by YB ‑1.KRASgene with about 30% mutations in all cancers, is considered the most commonly mutated oncogene in human cancers. Accumulating evidence indicates that oncogenic KRAS mediates CRT resistance. AKT and p90 ribosomal S6 kinase are downstream of KRAS and are the major kinases that stimulate YB ‑1 ...
Source: Strahlentherapie und Onkologie - June 2, 2023 Category: Cancer & Oncology Source Type: research
Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities
ConclusionOverall, there was good GTV agreement (DSC). Combined metrics appeared to allow a more valid detection of interobserver variation. For SBRT, either 4D PET/CT or 3D PET/CT in treatment position with abdominal compression leads to better agreement and should be considered as a very useful imaging modality for the definition of treatment volumes in pancreatic SBRT. Contouring d oes not appear to be the weakest link in the treatment planning chain of SBRT for PACA. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 2, 2023 Category: Cancer & Oncology Source Type: research
YB-1 activating cascades as potential targets in KRAS-mutated tumors
AbstractY ‑box binding protein‑1 (YB-1) is a multifunctional protein that is highly expressed in human solid tumors of various entities. Several cellular processes,e.g. cell cycle progression, cancer stemness and DNA damage signaling that are involved in the response to chemoradiotherapy (CRT) are tightly governed by YB ‑1.KRASgene with about 30% mutations in all cancers, is considered the most commonly mutated oncogene in human cancers. Accumulating evidence indicates that oncogenic KRAS mediates CRT resistance. AKT and p90 ribosomal S6 kinase are downstream of KRAS and are the major kinases that stimulate YB ‑1 ...
Source: Strahlentherapie und Onkologie - June 2, 2023 Category: Cancer & Oncology Source Type: research
Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities
ConclusionOverall, there was good GTV agreement (DSC). Combined metrics appeared to allow a more valid detection of interobserver variation. For SBRT, either 4D PET/CT or 3D PET/CT in treatment position with abdominal compression leads to better agreement and should be considered as a very useful imaging modality for the definition of treatment volumes in pancreatic SBRT. Contouring d oes not appear to be the weakest link in the treatment planning chain of SBRT for PACA. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 2, 2023 Category: Cancer & Oncology Source Type: research
High-dose planned adaptive helical tomotherapy for cutaneous angiosarcoma of the scalp
ConclusionPlanned adaptive high-dose IMRT with HT has the potential to improve local control rate without increasing adverse events. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 1, 2023 Category: Cancer & Oncology Source Type: research
Clinical outcome in metastatic prostate cancer after primary radiotherapy
ConclusionsDM was associated with significantly worse outcomes than NM. The long-term survival of patients with metastatic prostate cancer was low. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 1, 2023 Category: Cancer & Oncology Source Type: research
Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer
ConclusionWe demonstrated that dose-escalated RT for PCA up to 84 Gy is feasible and safe without a significant increase in acute toxicity. Further follow-up is needed to assess late toxicity and survival. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 1, 2023 Category: Cancer & Oncology Source Type: research
Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes
ConclusionLinac-based SBRT is a safe technique for performing Re‑I for intraprostatic recurrence after primary curative radiotherapy for PC. Future prospective, randomized studies are desirable to better understand the effectiveness of reirradiation and the still open questions in this field. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 1, 2023 Category: Cancer & Oncology Source Type: research
Safety and efficacy associated with single-fraction high-dose-rate brachytherapy in localized prostate cancer: a systematic review and meta-analysis
ConclusionSFHDR is associated with favorable tolerability and suboptimal clinical benefit in patients with localized prostate cancer. Ongoing and planned high-quality prospective studies are necessary to verify its safety and efficacy. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 1, 2023 Category: Cancer & Oncology Source Type: research
Preoperative radiotherapy with concomitant chemotherapy in extremity soft tissue sarcomas: long-term results of a single center
ConclusionAn increased risk for local failure seems to exist for patients with relapsed tumor on admission and having positive surgical margins after neoadjuvant RCT. Intensity of chemotherapy influenced DSS but not OS, which could be due to younger patients receiving MAP. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 1, 2023 Category: Cancer & Oncology Source Type: research
Brooke –Spiegler syndrome: radiotherapy as the last resort?
ConclusionThis case should remind us of the potential role that radiotherapy could play in treating Brooke –Spiegler syndrome. The required dose for treatment of such extensive disease is still a matter of debate due to the scarcity of radiotherapeutic experience. This case demonstrates that for scalp tumors, 30 × 2 Gy can result in long-term tumor control, while other dose prescriptions may be adequate for tumors in other locations. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 1, 2023 Category: Cancer & Oncology Source Type: research
Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial
ConclusionRobotic SBRT with 35 Gy in 5 fractions was associated with a favorable short-term toxicity profile. Recruitment for the HYPOSTAT‑2 trial (ARO-2018‑4; NCT03795337), which further analyses the late toxicity of this regimen with a planned sample size of 500 patients, is ongoing. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 1, 2023 Category: Cancer & Oncology Source Type: research
Gute Therapievertr äglichkeit und Lebensqualität nach primär organerhaltender Therapie des frühen Rektumkarzinoms: Ergebnisse der TREC-Studie
(Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 1, 2023 Category: Cancer & Oncology Source Type: research
Pr äoperative Therapie beim Pankreaskarzinom: Daten der A021501-Studie
(Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 1, 2023 Category: Cancer & Oncology Source Type: research
Re-Bestrahlung und Bevacizumab – wirksame Partner bei rezidiviertem Glioblastom
(Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - June 1, 2023 Category: Cancer & Oncology Source Type: research
